You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先聲藥業(02096.HK)中期歸母淨利6.04億元 同比增幅32.2%
格隆匯 08-21 21:30

格隆匯8月21日丨先聲藥業(02096.HK)公吿,截至2025年6月30日止6個月,集團錄得以下未經審核的財務業績:收入人民幣35.85億元,較2024年同期人民幣31.14億元增長15.1%。歸屬於公司權益股東的利潤人民幣6.04億元,較2024年同期人民幣4.57億元增加人民幣1.47億元,增幅32.2%。每股盈利0.25元

創新藥業務收入人民幣27.76億元,佔總收入比率77.4%,較2024年同期人民幣22.03億元增長26.0%。集團收入主要來自業務聚焦的治療領域。其中,神經科學領域收入人民幣12.49億元,佔總收入的34.8%,較2024年同期人民幣9.09億元增長37.3%;抗腫瘤領域收入人民幣8.74億元,佔總收入的24.4%,較2024年同期人民幣6.19億元增長41.1%;自身免疫領域收入人民幣8.78億元,佔總收入的24.5%,較2024年同期人民幣8.50億元增長3.3%;其他領域收入人民幣5.84億元,佔總收入的16.3%,較2024年同期人民幣7.36億元下降20.5%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account